Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 15/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709653 | 0.92 | REN (0.50) | REN | |
| SCHEMBL5709664 | 0.85 | REN (0.51) | REN | |
| SCHEMBL9249864 | 0.82 | REN (0.62) | REN | |
| SCHEMBL5709565 | 0.82 | REN (0.62) | REN | |
| SCHEMBL5709655 | 0.78 | REN (0.53) | RENALDH1A1 | |
| SCHEMBL9582660 | 0.78 | REN (0.53) | RENALDH1A1 | |
| SCHEMBL7345581 | 0.78 | REN (0.50) | REN | |
| SCHEMBL5709640 | 0.78 | REN (0.55) | REN | |
| SCHEMBL5709639 | 0.77 | REN (0.45) | RENALDH1A1 | |
| SCHEMBL9583268 | 0.76 | REN (0.45) | RENKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| EP-0431520-B1 | Heterocyclic acyl aminodiol beta-amino acid derivatives | SEARLE & CO (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5231111-A | Imidazolyl/imidazolylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-07-27 | — | — | US | disclosed |
| US-5223532-A | Chromonyl/chromonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino derivatives | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5223514-A | Renin inhibiros, hypotensive agents | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5223534-A | Renin inhibitors, hypotensive agents | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5217991-A | Renin inhibitors for treating hypertension | G. D. SEARLE & CO. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5217989-A | Benothiophenyl/benzothiophenylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5215996-A | Renin inhibitors; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5216013-A | Aralkyl-N-terminal cycloalkoxy-C terminal amino hydroxy β-amino acid derivatives | G. D. SEARLE & CO. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5212174-A | Renin inhibitors for hypotensive agents | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
| US-5180725-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1993-01-19 | — | — | US | disclosed |
| US-5180744-A | Renin inhibitors; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-01-19 | — | — | US | disclosed |
| US-5175181-A | Renin inhibitors, hypotensive agents | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5175170-A | Renin inhibitors, hypotensive agents | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5147888-A | Hypotensive agents; renin inhibitors | G. D. SEARLE & CO. (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0431520-A2 | Heterocyclic acyl aminodiol beta-amino acid derivatives | G.D. Searle & Co. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | MAPT 42/4885REN 2199/4885HPGD 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.